Novartis Vaccines Unit Makes Move Into Crowded CMV Competition
This article was originally published in The Pink Sheet Daily
Executive Summary
Licensing deal for AlphaVax’s Phase I CMV candidate also includes options for RSV vaccine candidate and 4 million share stock purchase.